Quintrio
Home

SERVICES-MEDICAL LABORATORIES

Veracyte, Inc.

VCYT

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Last trade $24.04
Day change +$0.03 (+0.12%)
Day range $23.59 – $26.62
Volume 1,427,525
Market cap $1.94B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.94B
Price / earnings
15.27×
Price / book
1.35×
Price / sales
3.33×
EV / sales
2.99×
EV / EBITDA
14.37×

Profitability

Earnings per share
$1.57
Return on assets
8.06%
Return on equity
8.85%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.56×
Quick ratio
5.25×
Cash ratio
2.37×

Cash flow

Price / cash flow
11.14×
Price / free cash flow
11.96×
Free cash flow
$161.95M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VCYT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$151.75M$150.32M$139.07M$140.64M$131.87M$130.16M$114.47M$118.63M
Cost of revenue$44.65M$41.77M$37.91M$38.66M$40.59M$40.4M$34.97M$39.88M
Gross profit$107.1M$108.55M$101.16M$101.97M$91.28M$89.77M$79.51M$78.75M
Selling, general and administrative$57.95M$55.71M$50.84M$43.31M$51.73M$57.65M$58.26M$51.74M
Research and development$32.16M$29.44M$27.1M$20.85M$15.98M$16.26M$17.72M$19.29M
Total operating expenses$90.54M$85.57M$78.51M$64.78M$68.34M$95.04M$76.6M$74.58M
Operating income$16.57M$22.98M$22.65M$37.2M$22.95M-$5.27M$2.9M$4.18M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$21.12M$26.52M$29.97M$40.63M$18.89M$1.25M$7.43M$3.44M
Income taxes-$10.38M$1.03M$1.27M-$515K-$248K$2.23M$381K-$1.67M
Net income$31.5M$25.49M$28.71M$41.15M$19.14M-$980K$7.05M$5.11M
Net income attributable to common shareholders$31.5M$25.49M$28.71M$41.15M$19.14M-$980K$7.05M$5.11M
EBITDA$22.55M$27.82M$28.08M$42.49M$28.21M$20.73M$8.27M$13.18M
Basic earnings per share$0.39$0.32$0.36$0.52$0.24-$0.01$0.09$0.07
Diluted earnings per share$0.38$0.31$0.35$0.49$0.24-$0.01$0.09$0.06

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment

Veracyte beat Q3 earnings and revenue estimates but cut its 2026 sales outlook due to slower-than-expected Decipher Prostate growth. The company expects 10% test volume growth in 2027 but only mid-single-digit revenue growth with a 22% EBITDA margin. Veracyte plans to expand its urology salesforce by 30% in 2027 while advancing Prosigna breast cancer and bladder cancer testing offerings.

GlobeNewswire Inc.

STRA SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES CLAIMS OF SECURITIES FRAUD AGAINST STRATEGIC EDUCATION, INC.

Law firm Ademi LLP is investigating potential securities fraud claims against Strategic Education (STRA), MNTN, and Veracyte (VCYT). STRA's stock has declined over 20% amid inaccurate statements regarding its Australian business operations, while VCYT has experienced a stock decline exceeding 50%. The firm is seeking affected shareholders to discuss their rights.

Zacks Investment Research

Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates

Veracyte reported Q3 2026 earnings of $0.51 per share, beating consensus estimates by 15.91%, with revenues of $151.75 million exceeding expectations by 3.06%. The company has outperformed market estimates in four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Instruments industry ranks in the top 43% of Zacks industries.

Zacks Investment Research

4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats

The healthcare sector is experiencing a familiar divide in Q3 2026 earnings: while demand remains solid with laboratories ordering more equipment and cancer testing expanding, profit growth is lagging with the sector projected to see a 0.9% earnings decline despite 5% revenue growth. Pricing pressure, uneven research spending, and higher operating costs are constraining margins. Four medical companies—Viatris, Revvity, Elanco Animal Health, and Veracyte—offer different perspectives on sector momentum, each with positive earnings indicators suggesting potential beats above consensus expectations.

GlobeNewswire Inc.

Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer

Veracyte announced new data from a Phase III STAMPEDE trial analysis showing its Decipher Prostate Genomic Classifier can predict which men with very high-risk nonmetastatic prostate cancer will benefit from adding abiraterone to androgen deprivation therapy. The retrospective analysis provides Level 1B predictive evidence, with patients having higher Decipher scores showing greater benefit (10-11% absolute reduction in distant metastasis at five years versus 2% for lower scores). The findings support broader adoption of the test for treatment-intensification decisions.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.